The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2024 | The importance of optimizing liver health before gene therapy and how this is accomplished
Preclinical models suggest that markers of liver health before receiving gene therapy for hemophilia may be predictive of the treatment outcome. Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, highlights the importance of optimizing liver health in patients undergoing gene therapy and outlines how this can be accomplished. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting and/or speaker fees from BioMarin, Pfizer, Bayer, Spark and Novo Nordisk
Research funding from Bayer
